FiercePharma

Pfizer, on third try, wins FDA nod for biosimilar of blockbuster Epogen/Procrit

After a couple of misfires, Pfizer has finally won FDA approval for its biosimilar of anemia drug Epogen/Procrit, a drug whose U.S. sales generated about $1.8 billion last year for partners Amgen and ...
Healio

FDA approves Retacrit, an Epogen/Procrit biosimilar, for treatment of anemia

Please provide your email address to receive an email when new articles are posted on . The FDA today approved epoetin alfa-epbx, the first epoetin alfa biosimilar, for the treatment of anemia caused ...
Monthly Prescribing Reference

Biosimilar Retacrit, an Erythropoiesis-Stimulating Agent, Now Available

Retacrit will be priced 57.1% below the Wholesale Acquisition Cost (WAC) of Procrit and 33.5% below the WAC of Epogen, at $11.03 per 1000 Units/mL. In addition, Retacrit is indicated for the reduction ...
Medscape

First Epoetin Alfa Biosimilar Approved in the US

The US Food and Drug Administration (FDA) has approved the first biosimilar erythropoiesis-stimulating agent. The reference product is epoetin alfa (Epogen/Procrit, Amgen). The new biosimilar is ...
Medscape

Aranesp, Procrit, Epogen Linked to Risks of Pure Red Cell Aplasia, Anemia

Dec. 2, 2005 -- The US Food and Drug Administration (FDA), Amgen Inc, and Ortho Biotech Clinical Affairs, LLC, have notified healthcare professionals via letter regarding revisions to the safety ...
Consumer Reports

Are anemia drugs safe?

The anemia drugs epoetin alfa (Procrit and Epogen) and darbepoetin alfa (Aranesp) are among the top-sellers in the U.S., as consumers and their insurance companies spent $7.2 billion in 2008 on this ...
Renal & Urology News

Higher Conversion Ratio for Epoetin Beta to Darbepoetin Alfa

Fixed-Dose Phosphate Binder Schedules May Be Less than Ideal Researchers confirmed higher dose conversion ratios in Taiwanese patients with stable hemoglobin. For Asian hemodialysis (HD) patients with ...
FierceBiotech

Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa)

THOUSAND OAKS, Calif., Sept. 24 /PRNewswire/ -- Amgen (Nasdaq: AMGN) announced today that certain lots of EPOGEN® and PROCRIT® (Epoetin alfa) vials are being voluntarily recalled from specialty ...
ascopubs.org

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.

Value of caregiver ratings in evaluating the quality of life of patients with cancer. More than 500 community-based oncologists enrolled 2,342 patients with malignancies undergoing cytotoxic ...
Healio

Provider evaluates methoxy polyethylene glycol-epoetin beta in peritoneal dialysis

There are more than 700,000 prevalent cases of end-stage kidney disease in the United States, which is increasing by approximately 20,000 cases per year. 1 Peritoneal dialysis is a home renal ...
ascopubs.org

Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer ...

The US Food and Drug Administration (FDA) has approved epoetin and darbepoetin for chemotherapy-induced anemia (CIA). Approved epoetin and darbepoetin dosing schedules were three times per week and ...